H3N2 Infection - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2016’, provides an overview of the H3N2 Infection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects
The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for H3N2 Infection
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- H3N2 Infection Overview
- Therapeutics Development
- Pipeline Products for H3N2 Infection - Overview
- Pipeline Products for H3N2 Infection - Comparative Analysis
- H3N2 Infection - Therapeutics under Development by Companies
- H3N2 Infection - Therapeutics under Investigation by Universities/Institutes
- H3N2 Infection - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- H3N2 Infection - Products under Development by Companies
- H3N2 Infection - Products under Investigation by Universities/Institutes
- H3N2 Infection - Companies Involved in Therapeutics Development
- AIMM Therapeutics B.V.
- Aphios Corporation
- Crucell N.V.
- CSL Limited
- Glide Pharmaceutical Technologies Limited
- ILiAD Biotechnologies, LLC
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Medicago Inc.
- MedImmune, LLC
- Mucosis B.V.
- NanoViricides, Inc.
- Novavax, Inc.
- OPKO Health, Inc.
- Sarepta Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- Visterra, Inc.
- Zydus Cadila Healthcare Limited
- H3N2 Infection - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- APP-0205 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- APP-309 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Aspidasept - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- C-05 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CR-8020 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CR-9114 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FluGEM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Gamma-Flu - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strain A/H3N2] vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strain A/H3N2] vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JNJ-872 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NVINF-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NVINF-2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- pertussis [strain BPZE1] vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PNSIA-28 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- radavirsen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules for RSV and Influenza A Infections - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TXB-248 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VIS-410 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- H3N2 Infection - Recent Pipeline Updates
- H3N2 Infection - Dormant Projects
- H3N2 Infection - Product Development Milestones
- Featured News & Press Releases
- Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
- Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for H3N2 Infection, H1 2016
- Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
- Number of Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Clinical Stage Development, H1 2016
- Comparative Analysis by Early Stage Development, H1 2016
- Products under Development by Companies, H1 2016
- Products under Development by Companies, H1 2016 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2016
- H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016
- H3N2 Infection - Pipeline by Aphios Corporation, H1 2016
- H3N2 Infection - Pipeline by Crucell N.V., H1 2016
- H3N2 Infection - Pipeline by CSL Limited, H1 2016
- H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016
- H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016
- H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
- H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016
- H3N2 Infection - Pipeline by Medicago Inc., H1 2016
- H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016
- H3N2 Infection - Pipeline by Mucosis B.V., H1 2016
- H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016
- H3N2 Infection - Pipeline by Novavax, Inc., H1 2016
- H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016
- H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016
- H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
- H3N2 Infection - Pipeline by Visterra, Inc., H1 2016
- H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
- Assessment by Monotherapy Products, H1 2016
- Assessment by Combination Products, H1 2016
- Number of Products by Stage and Target, H1 2016
- Number of Products by Stage and Mechanism of Action, H1 2016
- Number of Products by Stage and Route of Administration, H1 2016
- Number of Products by Stage and Molecule Type, H1 2016
- H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016
- H3N2 Infection - Dormant Projects, H1 2016
- List of Figures
- Number of Products under Development for H3N2 Infection, H1 2016
- Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
- Number of Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Clinical Stage Development, H1 2016
- Comparative Analysis by Early Stage Products, H1 2016
- Assessment by Monotherapy Products, H1 2016
- Assessment by Combination Products, H1 2016
- Number of Products by Targets, H1 2016
- Number of Products by Stage and Targets, H1 2016
- Number of Products by Mechanism of Actions, H1 2016
- Number of Products by Stage and Mechanism of Actions, H1 2016
- Number of Products by Top 10 Routes of Administration, H1 2016
- Number of Products by Stage and Routes of Administration, H1 2016
- Number of Products by Molecule Types, H1 2016
- Number of Products by Stage and Molecule Types, H1 2016